

**List of Articles Included with the TSEAC Briefing Materials
for Their Meeting on October 14, 2004**

- (ref # 13). Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. *Lancet* 2004;364:529-31
- (ref #15). Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet* 2004;363:417-21
- (ref #17). Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. *Lancet* 2004;364:527-9
- (ref #24). Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *J Pathol* 2004;203:733-9
- (ref #25). Wilson K, Ricketts MN. Transfusion transmission of vCJD: a crisis avoided? *Lancet* 2004;364:477-9
- (ref #26). Center for Biologics Evaluation and Research. United States Food and Drug Administration. Department of Health and Human Services. Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products (revised January 9, 2002). URL <<http://www.fda.gov/cber/gdlns/cjdvcjd.htm>>
- (ref #34). Foster PR. Removal of TSE agents from blood products. *Vox Sang* 2004;87 Suppl 2:7-10
- (ref#36). UK Department of Health. Patient notification exercise begins. Press Release. Sept 9, 2004 URL <http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4088953&chk=4BSn4F> (accessed Sept 20, 2004)